Alnylam Pharmaceuticals, Inc.
ALNY· Nasdaq
ALNYAlnylam Pharmaceuticals, Inc.
Filed Jul 28, 2022 · 10-Q · 28 days after period end · 0001178670-22-000020
| Metric | Q2 2022 | Q2 2021 | Q2 2020 | Q2 2019 |
|---|---|---|---|---|
| Revenue | $224.82M | $220.55M | $103.96M | $44.71M |
| Net Income | -$277.40M | -$189.56M | -$179.23M | -$219.48M |
| EPS Diluted | -$2.29 | -$1.61 | -$1.56 | -$2.02 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Alnylam Pharmaceuticals, Inc. · CIK 1178670 · Engraved from SEC EDGAR
ended Jun 30, 2022 · filed Jul 28, 2022 · 28 d after period end
